A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Contact:
NCT Number:
Protocol:
AAAV8032
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to test ARV-806 in people who have advanced cancer with KRAS G12D mutation. Advanced cancer is cancer that has spread or come back. KRAS G12D mutation is a change in the cancer DNA that may encourage cancer growth. ARV- 806 is experimental. This means that the Food and Drug Administration (FDA) has not approved the drug for sale or use for the treatment of advanced cancer with KRAS G12D mutation. This study is trying to find out the right dose of the drug that can be given without causing unacceptable side effects.
Are you Eligible? (Inclusion Criteria)
- Written informed consent obtained prior to the initiation of study procedures - Participants ≥18 years of age at the time of signing informed consent - Must be willing to provide blood and tumor tissue samples
Specialty Area(s)
Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Liver Cancer, Lung cancer, Pancreatic Cancer, Prostate Cancer, Sarcomas (Bone and Soft Tissue), Stomach Cancer, Thyroid Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
